Stay updated on Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Sign up to get notified when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.

Latest updates to the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe site’s revision tag changed from v3.6.3 to v3.6.4 to reflect an update.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page shows a new revision tag (v3.6.3), signaling a backend update; this change does not appear to affect the study details displayed.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page now displays a newer site revision label (v3.6.2) replacing the previous v3.6.0, indicating a software release for the page. This update does not alter the study details, eligibility criteria, or results displayed on the page.SummaryDifference0.1%

- Check53 days agoChange DetectedThe study page now shows that no participants are being sought, updating the recruitment status to completed. Additionally, new help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), and a small formatting change updated the Intervention/Treatment label while the site revision progressed from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check60 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing the previous Revision: v3.5.4, indicating an update to the page's versioning.SummaryDifference0.1%

- Check82 days agoChange DetectedA newer revision tag was added (v3.5.4) and the previous revision tag (v3.5.3) was removed, signaling an updated version of the study record.SummaryDifference0.1%

Stay in the know with updates to Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.